Intellia Therapeutics (NTLA) Financial Statements & Analysis

Intellia Therapeutics (NTLA) Income Statement

Intellia Therapeutics reported revenue of $67.67M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 16.9% from $57.88M a year earlier. Intellia Therapeutics posted a net loss of $412.69M, compared with a net loss of $519.02M a year earlier. Gross margin was 76.5% and operating margin -651.7%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $7.66M, down 46.2% from the same quarter a year earlier.

Intellia Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Intellia Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	67.67	57.88	36.28	52.12	33.05	57.99	43.10	30.43	26.12
Cost of Revenue	15.92	10.29	8.98	419.98	229.81	150.41	108.41	89.12	67.65
Gross Profit	51.75	47.59	27.30	52.12	33.05	-92.41	-65.31	-58.68	-41.53
Operating Expenses
Research & Development	388.86	466.31	435.07	419.98	229.81	150.41	108.41	89.12	67.65
Selling, General & Administrative	119.80	125.83	116.50	90.31	71.10	44.17	41.06	32.19	28.03
Operating Expenses	508.66	592.14	542.59	510.29	300.90	44.17	41.06	121.30	95.67
Operating Income	-440.99	-534.26	-515.29	-458.16	-267.85	-136.58	-106.37	-90.87	-69.56
Other Income/Expense
Interest Income	29.20	47.81	49.83	8.54	1.28	2.35	6.84	5.53	2.01
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	-0.90	-32.57	34.10	-16.02	-0.04	2.35	6.84	5.53	2.01
Income
Income Before Tax	-412.69	-519.02	-481.19	-474.19	-267.89	-134.23	-99.53	-85.34	-67.54
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-412.69	-519.02	-481.19	-474.19	-267.89	-134.23	-99.53	-85.34	-67.54
Net Income - Continuous Operations	-412.69	-519.02	-481.19	-474.19	-267.89	-134.23	-99.53	-85.34	-67.54
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-425.07	-523.98	-472.22	-450.59	-260.96	-130.27	-100.78	-86.41	-66.56
EBIT	-440.99	-534.26	-515.29	-458.16	-267.85	-136.58	-	-	-
Depreciation & Amortization	15.92	10.29	8.98	7.57	6.89	6.31	5.59	4.46	2.99
Earnings Per Share
Basic EPS	-4.00	-5.00	-5.00	-6.00	-4.00	-2.00	-2.00	-2.00	-2.00
Diluted EPS	-4.00	-5.00	-5.00	-6.00	-4.00	-2.00	-2.00	-2.00	-2.00
Basic Shares Outstanding	108.38	98.85	88.77	76.97	70.89	55.99	47.25	43.07	36.01
Diluted Shares Outstanding	108.38	98.85	88.77	76.97	70.89	55.99	47.25	43.07	36.01

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Intellia Therapeutics Financial Statements

What was Intellia Therapeutics's revenue in fiscal 2025?

Intellia Therapeutics reported revenue of $67.67M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 16.9% from $57.88M a year earlier.

Is Intellia Therapeutics profitable?

No. Intellia Therapeutics reported a net loss of $412.69M in fiscal 2025. In fiscal 2024 it lost $519.02M.

What is Intellia Therapeutics's operating margin?

Intellia Therapeutics's operating income was −$440.99M on revenue of $67.67M in fiscal 2025, an operating margin of -651.7%, compared with -923.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition